Market News (Page 2) - TendieTensor

Market News Page 2 of 235 • 5,857 articles

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Integer Holdings Corporation (ITGR) Shareholders

GlobeNewswire Inc. • Levi & Korsinsky, Llp

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Integer Holdings Corporation (ITGR) Shareholders

12/26/2025 04:56 PM • Levi & Korsinsky has filed a securities class action lawsuit against Integer Holdings Corporation on behalf of shareholders who suffered losses between July 25, 2024 and October 22, 2025. The complaint alleges that Integer made false statements about its competitive position in the electrophysiology manufacturing market, overstated customer demand visibility, and mischaracterized electrophysiology devices as a growth driver. Investors have until February 9, 2026 to request lead plaintiff status.

BAC - Buffett trimmed the position by 26.3 million shares, suggesting a measured approach to the financial sector
ITGR - The company is the subject of a securities fraud class action lawsuit alleging material misstatements about its competitive position, customer demand visibility, and product growth prospects in the electrophysiology market. These allegations indicate significant operational and disclosure failures that resulted in shareholder losses.

#securities fraud #class action lawsuit #electrophysiology devices #false statements #shareholder losses #cardio & vascular segment

DexCom, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before December 26, 2025 to Discuss Your Rights – DXCM

GlobeNewswire Inc. • Levi & Korsinsky, Llp

DexCom, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before December 26, 2025 to Discuss Your Rights – DXCM

12/26/2025 04:56 PM • DexCom faces a class action securities lawsuit alleging the company made unauthorized design changes to its G6 and G7 glucose monitoring devices without FDA approval, rendering them less reliable and presenting health risks to users. The complaint claims defendants overstated the devices' enhancements and concealed the true scope of issues, exposing the company to regulatory scrutiny and significant financial harm. Investors who suffered losses between January 8, 2024 and September 17, 2025 can join the lawsuit.

DXCM - The company faces serious allegations of securities fraud, unauthorized product design changes, FDA violations, and concealment of health risks associated with its medical devices. These factors pose significant legal, regulatory, and reputational risks that negatively impact investor confidence and shareholder value.

#securities fraud #class action lawsuit #glucose monitoring devices #FDA violations #product reliability #investor losses

You Don’t Need Big Money for These 3 Under-$30 Stock Plays

Investing.com • Chris Markoch

You Don’t Need Big Money for These 3 Under-$30 Stock Plays

12/26/2025 02:45 PM • The article highlights three under-$30 stocks suitable for investors with limited capital: Nintendo (NTDOY), which faces RAM cost pressures but maintains strong Switch 2 sales forecasts; NU Holdings (NU), a Latin American fintech showing 61% YTD growth with expansion plans; and Carnival Cruise Lines (CCL), which has recovered with 21% YTD gains and reinstated its dividend.

AMGN - Mentioned as a strategic collaboration partner with no specific details provided
NTDOY - Despite recent 21.7% decline due to RAM cost pressures, the company increased Switch 2 sales forecast from 15M to 19M units and maintains current pricing through supplier contracts. Stock trades under $20, presenting a bargain opportunity if sales targets are met.

#under-$30 stocks #low-priced stocks #growth potential #Nintendo Switch 2 #fintech #cruise lines #dividend reinstatement

GlobeNewswire Inc. • Not Specified

Fitell Corporation Announces Interim Dividend and Shareholder Loyalty Program

12/26/2025 01:58 PM • Fitell Corporation announced an interim dividend of $0.10 per share payable January 13, 2026, and a one-time shareholder loyalty program offering up to $0.15 per share in three tranches for shareholders who maintain book-entry ownership for 30-90 days. The initiatives reflect the company's improved cash position and commitment to returning value to shareholders while supporting growth in fitness, corporate treasury management, and robotics ventures.

FTEL - The company is returning capital to shareholders through both an interim dividend and a loyalty program, indicating improved financial health and cash position. Management expressed confidence in the balance sheet and operational outlook, and the company is expanding into new growth areas including robotics ventures.

#interim dividend #shareholder loyalty program #book-entry transfer #capital return #fitness equipment #robotics joint-venture #2F Robotics

Microsoft Faces a Key Question: Compounder at Any Price or Accumulate Slowly

Investing.com • Itai Smidt

Microsoft Faces a Key Question: Compounder at Any Price or Accumulate Slowly

12/26/2025 01:48 PM • Microsoft trades at $486.72 with a P/E of 34.65, priced as a premium compounder. The company shows strong fundamentals with 18.43% revenue growth, 25.15% EPS growth, and 35.72% net margins. However, the valuation depends on three critical pillars: AI CapEx normalization by FY2028, continued Azure/AI growth at high double digits, and monetization of OpenAI/Anthropic relationships. Material risks include potential AI infrastructure overbuild, competition from Google and Amazon, and OpenAI financing/governance risks. Despite these risks, the analyst rates MSFT as a Buy given its strong financial performance and structural advantages.

MSFT - Strong financial metrics (18%+ revenue growth, 25%+ EPS growth, 35%+ net margins, 20%+ return on capital) and strategic positioning in AI/cloud with Azure growing at 39%. Analyst rates as Buy despite premium valuation. Positive outlook contingent on successful AI CapEx deployment and continued market dominance.

#Microsoft #AI infrastructure #Azure #valuation #CapEx #OpenAI #cloud computing #earnings growth #competitive risks

DEADLINE ALERT for FCX, PRGO, JYD, STUB: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions

GlobeNewswire Inc. • Law Offices Of Howard G. Smith

DEADLINE ALERT for FCX, PRGO, JYD, STUB: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions

12/26/2025 12:56 PM • Law Offices of Howard G. Smith has announced securities fraud class action lawsuits against four publicly-traded companies: Freeport-McMoRan (FCX) for safety issues at its Indonesian mine, Perrigo Company (PRGO) for undisclosed problems with its acquired infant formula business, Jayud Global Logistics (JYD) for involvement in a fraudulent stock promotion scheme, and StubHub Holdings (STUB) for misleading cash flow reporting. Investors have until January 2026 to file lead plaintiff motions.

FCX - Company faces securities fraud allegations for failing to disclose inadequate safety measures at its Grasberg mine in Indonesia, creating undisclosed regulatory and reputational risks.

#securities fraud #class action lawsuit #lead plaintiff deadline #false statements #misleading disclosures #investor losses

Deadline Alert: CarMax, Inc. (KMX) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit

GlobeNewswire Inc. • Glancy Prongay & Murray Llp

Deadline Alert: CarMax, Inc. (KMX) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit

12/26/2025 12:49 PM • CarMax faces a securities fraud class action lawsuit after the company disclosed significant revenue and profit declines in Q2 2026 results on September 25, 2025. The lawsuit alleges CarMax made materially false statements about growth prospects, which were allegedly driven by temporary tariff-related speculation rather than sustainable business fundamentals. The stock fell 20.1% following the disclosure. Investors have until January 2, 2026 to file a lead plaintiff motion.

PIPR - Mentioned as conference host facilitating investor interactions
KMX - CarMax disclosed significant financial deterioration (6% revenue decline, 7.2% retail vehicle revenue decline, 5.6% gross profit decline) and faces securities fraud allegations for allegedly overstating growth prospects. The stock experienced a sharp 20.1% decline on the news, and the company is accused of misleading investors about the sustainability of its earlier growth.

#securities fraud #class action lawsuit #revenue decline #misleading statements #tariff speculation #inventory right-sizing #loan loss provisions

Silver Jumps 6%, Platinum Up 8%, Palladium Up 11% As Metal Shock Erupts: What's Moving Markets Friday?

Benzinga • Piero Cingari

Silver Jumps 6%, Platinum Up 8%, Palladium Up 11% As Metal Shock Erupts: What's Moving Markets Friday?

12/26/2025 12:47 PM • Precious and industrial metals surged on December 26, 2025, with silver up 6% to $76/oz, platinum up 8%, and palladium up 11%, driven by supply crunches in Asian markets. Silver and platinum are on track for their best years since 1978 and on record, respectively. Gold rose 1.3% to $4,550/oz while copper climbed 4.6%. Among equities, copper producer Freeport-McMoRan led gains at +3%, while the S&P 500 remained flat near 5,930 points.

FCX - Copper producer led S&P 500 gainers with +3% gain, benefiting from copper's 4.6% climb as it recovers from July selloff.

#precious metals #silver #platinum #palladium #supply crunch #copper #gold #market volatility #year-to-date gains

Eli Lilly’s New Drug Data Sets Up a High-Stakes 2026

Investing.com • Leo Miller

Eli Lilly’s New Drug Data Sets Up a High-Stakes 2026

12/26/2025 12:44 PM • Eli Lilly released promising clinical trial data for two next-generation weight loss and diabetes drugs in late 2025. Orforglipron, an oral GLP-1 pill, showed patients maintained 80-95% of weight loss when switching from injectables. Retatrutide demonstrated superior weight loss (28.7% vs 20.2% for current drugs) but had higher discontinuation rates. The company faces critical FDA approval decisions and additional trial readouts in 2026 that could significantly impact its stock performance.

LLY - Company demonstrated strong clinical trial results for next-generation drugs with potential to expand market reach through oral formulations and superior weight loss efficacy. Stock gained 71% year-to-date and company achieved $1 trillion market cap. However, sentiment is tempered by execution risks including FDA approval uncertainty and elevated discontinuation rates in retatrutide trials.

#weight loss drugs #GLP-1 medications #orforglipron #retatrutide #clinical trial data #FDA approval #pharmaceutical innovation #tirzepatide #Zepbound #Mounjaro

Deadline Alert: Primo Brands Corporation (PRMB) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit

GlobeNewswire Inc. • Glancy Prongay & Murray Llp

Deadline Alert: Primo Brands Corporation (PRMB) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit

12/26/2025 12:43 PM • Glancy Prongay & Murray LLP is alerting Primo Brands Corporation investors to a January 12, 2026 deadline to file a lead plaintiff motion in a securities fraud class action. The lawsuit alleges that Primo Brands made materially false statements regarding its merger integration with BlueTriton Brands, failing to disclose major supply disruptions and operational issues. Stock prices fell significantly following disclosures in August 2025 (9.1% decline) and November 2025 (36.2% decline over two days) when the company admitted integration problems and replaced its CEO.

QCOM - Invested in Classiq and aligned with vision of enabling intelligent edge and cloud systems
PRMB - The company is the subject of a securities fraud lawsuit alleging material misstatements and non-disclosure of merger integration problems and supply disruptions. Stock declined 9.1% in August 2025 and 36.2% in November 2025 following negative operational disclosures and CEO replacement, indicating significant investor losses and loss of confidence.

#securities fraud #class action lawsuit #merger integration #supply disruptions #stock price decline #CEO replacement #guidance reduction

Deadline Alert: Sprouts Farmers Market, Inc. (SFM) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit

GlobeNewswire Inc. • Glancy Prongay & Murray Llp

Deadline Alert: Sprouts Farmers Market, Inc. (SFM) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit

12/26/2025 12:43 PM • A class action lawsuit has been filed against Sprouts Farmers Market (SFM) alleging securities fraud. The company announced weaker-than-expected Q3 2025 results with comparable-store sales growth of 5.9% and slashed full-year guidance to flat to 2% growth, citing previously undisclosed challenging comparisons and softening consumer demand. The stock fell 26.1% on the news. Investors who purchased SFM securities between June 4 and October 29, 2025 have until January 26, 2026 to file a lead plaintiff motion.

SFM - The company is facing a securities fraud lawsuit alleging material misstatements and non-disclosure of adverse business conditions. Q3 results significantly missed expectations with comparable-store sales of 5.9% versus prior guidance, full-year guidance was slashed to flat to 2% growth, and the stock experienced a sharp 26.1% decline. The lawsuit alleges defendants failed to disclose weakening consumer demand and unsustainable growth metrics.

#securities fraud #class action lawsuit #comparable-store sales #guidance reduction #stock decline #investor losses #misleading statements

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm Encourages Charming Medical Limited (MCTA) Shareholders to Inquire About Securities Fraud Class Action

Benzinga • Business Wire

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm Encourages Charming Medical Limited (MCTA) Shareholders to Inquire About Securities Fraud Class Action

12/26/2025 12:43 PM • A securities fraud class action lawsuit has been filed against Charming Medical Limited (NASDAQ: MCTA) on behalf of investors who purchased shares between October 10 and November 12, 2025. The SEC halted trading of MCTA securities due to potential market manipulation involving social media-based fraudulent stock promotion schemes. The complaint alleges that company defendants made materially false statements and failed to disclose the fraudulent promotion scheme, insider share dumping, and artificial trading activity driving the stock price.

MCTA - The company is the subject of a securities fraud class action lawsuit, SEC trading halt, and allegations of involvement in a fraudulent stock promotion scheme involving market manipulation, false statements, insider share dumping, and artificial trading activity designed to inflate stock price.

#securities fraud #class action lawsuit #market manipulation #social media promotion #SEC trading halt #shareholder rights #stock price inflation

Deadline Alert: Stride, Inc. (LRN) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit

GlobeNewswire Inc. • Glancy Prongay & Murray Llp

Deadline Alert: Stride, Inc. (LRN) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit

12/26/2025 12:39 PM • Glancy Prongay & Murray LLP is alerting Stride, Inc. investors about a class action securities fraud lawsuit with a January 12, 2026 deadline to file a lead plaintiff motion. The lawsuit alleges that Stride made false statements and failed to disclose material facts about inflated enrollment numbers through 'ghost students,' inadequate staffing, compliance violations, and suppressed whistleblowers. The company's stock fell 11.7% on September 15, 2025 following fraud allegations and another 54.4% on October 29, 2025 after disappointing Q1 fiscal 2026 results.

IONQ - Invested in Classiq and sees partnership as enabling cutting-edge quantum applications
LRN - Stride faces serious allegations of securities fraud including inflating enrollment numbers with 'ghost students,' ignoring compliance requirements, suppressing whistleblowers, and making materially false statements to investors. The company experienced significant stock price declines (11.7% and 54.4%) following disclosure of these issues and disappointing financial results, indicating substantial investor losses and reputational damage.

#securities fraud #class action lawsuit #enrollment fraud #ghost students #compliance violations #stock decline #lead plaintiff #material misstatement

The Motley Fool • Bram Berkowitz

Ed Yardeni Steps Back From the "Magnificent Seven" and Bets on the Impressive 493 Instead

12/26/2025 12:37 PM • Investment strategist Ed Yardeni is shifting from a bullish stance on the Magnificent Seven tech stocks to a more neutral position, instead favoring the remaining 493 S&P 500 companies. He believes all companies are becoming technology companies and recommends focusing on industrials, financials, and healthcare sectors, which offer better valuations and risk-reward scenarios compared to expensive AI-driven tech stocks.

IONQ.WS - Invested in Classiq and sees partnership as enabling cutting-edge quantum applications
MAGX - Yardeni is shifting from bullish to neutral on these stocks due to concerns about excessive valuations, concentration risk (35% of S&P 500), and uncertainty about whether AI infrastructure investments will deliver promised returns. Increased competition from smaller tech companies and each other may erode margins.

#Magnificent Seven #S&P 500 #tech stocks #artificial intelligence #valuations #healthcare sector #financials sector #industrials sector #market concentration

ARE Investors Have Opportunity to Lead Alexandria Real Estate Equities, Inc. Securities Fraud Lawsuit with the Schall Law Firm

GlobeNewswire Inc. • The Schall Law Firm

ARE Investors Have Opportunity to Lead Alexandria Real Estate Equities, Inc. Securities Fraud Lawsuit with the Schall Law Firm

12/26/2025 11:50 AM • The Schall Law Firm is seeking investors in a class action securities fraud lawsuit against Alexandria Real Estate Equities, Inc. (ARE) for making false and misleading statements about leasing spreads and occupancy growth for its life-science properties between January 27, 2025 and October 27, 2025. Investors who suffered losses are encouraged to join the case by January 26, 2026.

ARE - The company is accused of making false and misleading statements to investors regarding leasing spreads and occupancy growth for its life-science properties, resulting in investor losses. A securities fraud class action lawsuit has been filed against the company for violations of the Securities Exchange Act.

#securities fraud #class action lawsuit #Alexandria Real Estate Equities #misleading statements #leasing spreads #occupancy growth #shareholder rights

JYD Investors Have Opportunity to Lead Jayud Global Logistics Limited Securities Fraud Lawsuit with the Schall Law Firm

GlobeNewswire Inc. • The Schall Law Firm

JYD Investors Have Opportunity to Lead Jayud Global Logistics Limited Securities Fraud Lawsuit with the Schall Law Firm

12/26/2025 11:40 AM • The Schall Law Firm is seeking investors who purchased Jayud Global Logistics Limited (NASDAQ: JYD) securities between April 21, 2023 and April 30, 2025 to join a class action lawsuit alleging securities fraud. The company allegedly made false and misleading statements, benefited from a fraudulent stock promotion scheme involving impersonated financial professionals, and used offshore accounts to dump inflated shares.

JYD - The company is accused of making false and misleading statements, participating in fraudulent stock promotion schemes with impersonated financial professionals, and using offshore accounts to dump shares at inflated prices, resulting in investor losses.

#securities fraud #class action lawsuit #false statements #stock promotion scheme #offshore accounts #share dumping #investor losses

PRMB Investors Have Opportunity to Lead Primo Brands Corporation Securities Fraud Lawsuit with the Schall Law Firm

GlobeNewswire Inc. • The Schall Law Firm

PRMB Investors Have Opportunity to Lead Primo Brands Corporation Securities Fraud Lawsuit with the Schall Law Firm

12/26/2025 11:00 AM • The Schall Law Firm is seeking investors who purchased Primo Brands Corporation (PRMB) securities between June 2024 and November 2025 to join a class action lawsuit alleging securities fraud. The company allegedly made false and misleading statements about its merger with BlueTriton Brands, claiming it was proceeding 'flawlessly' while failing to disclose material facts about integration progress. Investors are encouraged to contact the firm before January 12, 2026.

TTE - Proactively transitioning to renewable energy, 17% clean energy growth in 2024, 6.1% dividend yield, committed to energy transition unlike peers
PRMB - The company is accused of making false and misleading statements regarding its merger with BlueTriton Brands, failing to disclose material facts about integration progress, and misrepresenting the merger as proceeding 'flawlessly' when it was not. This resulted in investor losses and triggered a securities fraud class action lawsuit.

#securities fraud #class action lawsuit #Primo Brands Corporation #merger #BlueTriton Brands #false statements #investor losses

SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Freeport-McMoran

GlobeNewswire Inc. • Faruqi & Faruqi, Llp

SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Freeport-McMoran

12/26/2025 10:55 AM • A securities class action has been filed against Freeport-McMoran for allegedly making false statements about safety at its Grasberg Block Cave mine in Indonesia. Following a September 2025 incident where a wet material flow trapped seven workers, resulting in two deaths and five missing, the company's stock fell significantly. The lawsuit alleges the company failed to disclose inadequate safety precautions and heightened regulatory and reputational risks. The deadline to seek lead plaintiff status is January 12, 2026.

FCX - The company faces a federal securities class action alleging it made false/misleading statements about safety at its Indonesian mine. A tragic incident resulted in worker deaths and significant stock price declines (5.9%, 17%, and 6.2% on consecutive days in September 2025). The lawsuit claims inadequate safety precautions and undisclosed regulatory and reputational risks, indicating serious operational and legal challenges.

#securities litigation #class action lawsuit #mining safety #Grasberg mine #Indonesia #worker deaths #stock price decline #regulatory risk #false statements #lead plaintiff

SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Telix Pharmaceuticals

GlobeNewswire Inc. • Faruqi & Faruqi, Llp

SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Telix Pharmaceuticals

12/26/2025 10:55 AM • A federal securities class action has been filed against Telix Pharmaceuticals for allegedly making false and misleading statements about its prostate cancer therapeutic candidates and supply chain quality. The company received an SEC subpoena in July 2025 and an FDA Complete Response Letter in August 2025 citing manufacturing deficiencies, resulting in significant stock price declines of 13% and 21% respectively. Investors who purchased securities between February 21 and August 28, 2025 are encouraged to contact the law firm by the January 9, 2026 deadline to seek lead plaintiff status.

XOM - Mentioned as industry peer with strong dividend history, but not primary focus of recommendation
TLX - The company faces federal securities litigation alleging material misstatements about drug development progress and supply chain quality. SEC subpoena and FDA rejection of a key product application citing manufacturing deficiencies resulted in significant stock price declines (13-21%), indicating serious regulatory and operational challenges.

#securities fraud #class action lawsuit #prostate cancer therapeutics #FDA Complete Response Letter #manufacturing deficiencies #SEC investigation #investor losses

SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Stride

GlobeNewswire Inc. • Faruqi & Faruqi, Llp

SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Stride

12/26/2025 10:53 AM • A securities class action has been filed against Stride, Inc. (NYSE: LRN) alleging the company made false statements about its products and services while inflating enrollment numbers, cutting costs improperly, and ignoring compliance requirements. The allegations emerged after a September 2025 complaint from Gallup-McKinley County Schools and October 2025 earnings revelations of enrollment challenges, causing significant stock price declines of 11.7% and up to 51% respectively.

LRN - The company faces serious allegations of fraud, including inflating enrollment numbers with 'ghost students,' improper cost-cutting, and compliance violations. Stock price declined 11.7% on initial fraud allegations and up to 51% following earnings revelations of enrollment challenges and execution issues, resulting in a federal securities class action lawsuit.

#securities litigation #class action #fraud allegations #enrollment inflation #compliance violations #stock price decline #lead plaintiff deadline

SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Firefly

GlobeNewswire Inc. • Faruqi & Faruqi, Llp

SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Firefly

12/26/2025 10:53 AM • A securities law firm is investigating Firefly Aerospace for allegedly making false statements about its Spacecraft Solutions demand and Alpha rocket program viability. Following disappointing Q2 earnings (revenue down 26.2% YoY, Spacecraft Solutions down 49%) and a failed Alpha Flight 7 rocket test in late September 2025, the company's stock plummeted 36% in two weeks. Investors have until January 12, 2026 to seek lead plaintiff status in the class action lawsuit.

RIVN - Mentioned as a conference participant with no specific context about their performance or activities
FLY - Company faces federal securities fraud allegations for misrepresenting demand and operational readiness. Q2 earnings significantly missed expectations with 26.2% revenue decline and 49% drop in key business segment. Two rocket launch failures (April and September 2025) raised viability concerns. Stock price fell 36% over two weeks following disclosures.

#securities fraud #class action lawsuit #IPO #rocket launch failure #earnings miss #stock decline #aerospace #lead plaintiff

SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of CarMax

GlobeNewswire Inc. • Faruqi & Faruqi, Llp

SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of CarMax

12/26/2025 10:50 AM • Faruqi & Faruqi, LLP is investigating potential securities law violations by CarMax, alleging the company made false statements about growth prospects that were temporarily boosted by tariff-related speculation. Following the September 25, 2025 disclosure of an 11.2% decrease in CarMax Auto Finance income and increased loan loss provisions, CarMax stock fell approximately 20% to $45.60 per share. The firm is seeking a lead plaintiff for the class action lawsuit with a January 2, 2026 deadline.

KMX - CarMax faces a federal securities class action lawsuit alleging executives made false and misleading statements about growth prospects. The company disclosed significantly increased loan loss provisions and a 20% stock price decline following earnings results, indicating deteriorating financial performance and investor confidence.

#securities litigation #class action lawsuit #false statements #loan loss provisions #stock price decline #tariff speculation #lead plaintiff

ECD Auto Design Expands 2026 Lineup With Heritage Coupes, Classic SUVs

Benzinga • Akanksha Bakshi

ECD Auto Design Expands 2026 Lineup With Heritage Coupes, Classic SUVs

12/26/2025 10:48 AM • ECD Automotive Design announced a major expansion of its 2026 product lineup, introducing heritage-inspired coupes, classic SUVs, and modern lifestyle 4x4s. The company is restructuring its classic SUV business into Heritage and Custom divisions with dedicated production lines, adding modern safety features like ABS and remote locking systems. ECD is also expanding modern programs through Chelsea Truck Company USA across multiple platforms including Land Rover Defender, Range Rover, and Toyota Land Cruiser. The company implemented a 1-for-5 reverse stock split effective December 26, 2025.

ECDA - The company announced a comprehensive expansion of its 2026 product lineup with new model families, deeper engineering refinement, and broader integration of modern features. CEO highlighted 2026 as a 'breakthrough year' with the most comprehensive portfolio to date. However, the recent reverse stock split may indicate prior stock price weakness, which is a cautionary note.

#product expansion #heritage vehicles #classic SUVs #modern safety features #reverse stock split #bespoke automotive manufacturing #Chelsea Truck Company USA

SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience

GlobeNewswire Inc. • Faruqi & Faruqi, Llp

SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience

12/26/2025 10:47 AM • Law firm Faruqi & Faruqi is investigating potential securities fraud claims against Skye Bioscience following the company's announcement that its drug nimacimab failed to meet primary endpoints in a Phase 2a clinical trial. The disclosure of lower-than-expected drug exposure and failure to achieve weight loss compared to placebo resulted in a 60% stock price decline on October 6, 2025. Investors who purchased securities between November 4, 2024 and October 3, 2025 are encouraged to contact the firm, with a January 16, 2026 deadline to seek lead plaintiff status.

MRSN - Being acquired at $25 per share with potential additional milestone payments, representing a strategic exit for the company
SKYE - The company faces securities litigation alleging false and misleading statements about its drug candidate nimacimab's effectiveness. The clinical trial failure resulted in a 60% stock price drop, and executives are accused of overstating the drug's clinical, regulatory, and commercial prospects.

#securities fraud #class action lawsuit #clinical trial failure #nimacimab #stock price decline #lead plaintiff #drug development

Colgate Looks Mispriced as Value, Yield, and Buybacks Start to Line Up

Investing.com • Thomas Hughes

Colgate Looks Mispriced as Value, Yield, and Buybacks Start to Line Up

12/26/2025 10:41 AM • Colgate-Palmolive (CL) is positioned as an attractive buy-and-hold opportunity for consumer staples investors. The stock trades at historically low valuations with a 2.65% dividend yield, strong capital return programs including a $5 billion buyback authorization, and technical indicators suggesting a potential reversal in early 2026. Analysts forecast potential 100% upside over 5-10 years as the company is expected to accelerate growth with a low bar set for Q4 results.

CL - The article presents multiple bullish catalysts including historically low valuations relative to historical norms, a reliable high-yielding dividend (2.65%), active share buyback program ($5 billion authorization), institutional accumulation throughout 2025, technical chart setup suggesting a bottom formation with bullish momentum indicators, and analyst expectations for accelerating growth with low Q4 expectations setting up for potential outperformance. Forecasts suggest 100% stock price upside over 5-10 years.

#Colgate-Palmolive #dividend aristocrat #value investing #share buybacks #technical reversal #consumer staples #capital returns